Baxter International (BAX) vs Haemonetics (HAE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Haemonetics (HAE) has outperformed Baxter International (BAX) over the past year, gaining 106.5% versus a gain of 4.7%. Over five years, HAE leads with a +45.5% price change compared with -69.9% for BAX. Baxter International is the larger company by market cap ($12.36 billion vs $5.44 billion), about 2.3 times the size.
On valuation, Baxter International trades at a lower forward P/E (11.7x vs 20.7x for Haemonetics). Baxter International pays a dividend yielding 0.84%, while Haemonetics does not currently pay one. Haemonetics converts more of its revenue into profit, with a net margin of 7.3% versus -8.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BAX | HAE |
|---|---|---|
| Share price | $23.90 | $119.47 |
| Market cap | $12.36B | $5.44B |
| 1-day change | -0.29% | +17.46% |
| YTD return | +25.43% | +26.90% |
| 1-year return | +4.67% | +106.48% |
| 5-year return | -69.92% | +45.49% |
| P/E ratio (TTM) | — | 57.71 |
| Forward P/E | 11.72 | 20.68 |
| EPS (TTM) | $-1.88 | $2.07 |
| Dividend yield | 0.84% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| Revenue (latest FY) | $11.24B | $1.33B |
| Revenue growth (YoY) | +5.72% | -1.97% |
| Net income (latest FY) | $-957.00M | $97.31M |
| Gross margin | 30.05% | 59.04% |
| Operating margin | -2.74% | 11.75% |
| Net margin | -8.51% | 7.29% |
| 52-week high | $30.00 | $120.72 |
| 52-week low | $15.73 | $48.17 |
| Distance from 52-week high | -20.33% | -1.04% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +16.82% | -6.67% |
| Average volume | 6.60M | 678.94K |
| Shares outstanding | 517.00M | 45.50M |
| Employees | 37,500 | 3,009 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Baxter International is about 2.3 times larger than Haemonetics by market value ($12.36B vs $5.44B).
- HAE has outperformed BAX by 101.8 percentage points over the past year.
- Haemonetics is more profitable, keeping 7.3 cents of every revenue dollar as net income versus -8.5 cents for Baxter International.
- Baxter International grew revenue faster in its latest fiscal year (+5.72% vs -1.97%).
About Baxter International
BAX stock →Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Health Care · Medical/Dental Instruments · 37,500 employees
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
BAX vs HAE FAQ
Which is bigger, Baxter International or Haemonetics?
Baxter International (BAX) is larger, with a market capitalization of $12.36B compared with $5.44B for Haemonetics (HAE).
Which stock has performed better over the past year, BAX or HAE?
HAE returned +106.48% over the past 12 months, compared with +4.67% for BAX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Baxter International or Haemonetics?
Baxter International pays a dividend yielding 0.84%, while Haemonetics does not currently pay a regular dividend.
Are Baxter International and Haemonetics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.